Full Press Release Details
| Contact: | Pete De Spain | |
| Sr. Director, Investor Relations | ||
| Corporate Communications | ||
| 858-792-3729 | ||
| pete.despain@marshalledwardsinc.com |
MARSHALL EDWARDS APPOINTS ONCOLOGIST CHRISTINE WHITE TO
San Diego August 10, 2010 Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology
company focused on the clinical development of novel anti-cancer therapeutics, announced today the
appointment of Christine A. White, M.D., to its board of directors. Dr. White replaces Professor
Paul J. Nestel, who has served as a director since April 2001.
Dr. White brings a unique and valuable perspective to our board as we continue to build a
world-class oncology organization here in the U.S., said Daniel P. Gold, Ph.D., President and
Chief Executive Officer of Marshall Edwards. Her deep understanding of drug development and
regulatory affairs coupled with her years of experience treating patients as a clinical oncologist
will be a valuable asset to the company.
Dr. White was with Biogen Idec from 1996 to 2005, most recently as Senior Vice President, Global
Medical Affairs, where she played an integral role in the clinical development, regulatory affairs
and commercialization of oncology drugs Rituxan and Zevalin . Previously,
she served as the Director of Clinical Oncology Research at the Sidney Kimmel Cancer Center in San
Diego, and in the Department of Medicine at Scripps Memorial Hospitals in La Jolla and Encinitas,
California, most recently as Chairman.
Dr. White currently serves as a member of the board of directors of Arena Pharmaceuticals, a
clinical-stage biopharmaceutical company, and Genoptix, a specialized laboratory services provider.
She also served as a director of Pharmacyclics, a biopharmaceutical company, and Monogram
Biosciences, a life sciences company, until its acquisition by LabCorp in August 2009. Dr. White
earned her B.A. in Biology and her M.D. from the University of Chicago and is Board certified in
both Internal Medicine and Medical Oncology.
I am very pleased to welcome Dr. White to the board and look forward to working with her as we
strive to build long-term shareholder value, said Professor Bryan R.G. Williams, Chairman of the
board of directors of Marshall Edwards. I also want to take this opportunity on behalf of the
entire board to thank Professor Nestel for his years of dedicated service to Marshall Edwards.
About Marshall Edwards, Inc.
Marshall Edwards, Inc. (NASDAQ: MSHL) is a San Diego-based oncology company focused on the clinical
development of novel anti-cancer therapeutics. These derive from an investigational isoflavone
technology platform, which has generated a number of novel compounds characterized by direct
targeting of tumor metabolism. Specifically, these compounds are believed to target an enzyme
present in the cell membrane of cancer cells, thereby inhibiting the production of pro-survival
proteins within the cell. Marshall Edwards has licensed rights from Novogen Limited (ASX: NRT;
NASDAQ: NVGN) for oncology drug candidates Phenoxodiol, Triphendiol, NV-143 and NV-128. For more
information, please visit www.marshalledwardsinc.com.
Rituxan is a registered trademark of Genentech.
Zevalin is a registered trademark of Biogen Idec.
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials
and approved by the FDA as being safe and effective for the intended use. Statements included in
this press release that are not historical in nature are forward-looking statements within the
meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
You should be aware that our actual results could differ materially from those contained in the
forward-looking statements, which are based on management s current expectations and are subject to
a number of risks and uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development and/or FDA approval, or
the failure to obtain such approval, of our product candidates; uncertainties or differences in
interpretation in clinical trial results; our inability to maintain or enter into, and the risks
resulting from our dependence upon, collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and distribution of any products;
competitive factors; our inability to protect our patents or proprietary rights and obtain
necessary rights to third party patents and intellectual property to operate our business; our
inability to operate our business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market acceptance; our inability
to obtain any additional required financing; technological changes; government regulation; changes
in industry practice; and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking statements.